Immunome Q2 Loss Widens to $73.1M, Cash Burn Accelerates
IMNM has more than doubled off its 52-week low of $8.665.
Summary
Immunome posted a $73.1M net loss for Q2 2026, a sharp increase from the $53.8M loss in Q1. The widening loss signals accelerating cash burn, with cash reserves of $582.7M as of last quarter now likely eroding faster. This follows a series of insider stock sales totaling over $5.7M in recent months, adding to concerns about capital needs. The company recently dosed its first patient in a Phase 1 trial for IM-3050, but the rising loss rate puts pressure on the balance sheet. Immunome expects its current cash position to fund operations into 2028.
At the time of this announcement, IMNM was trading at $26.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $8.67 to $27.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.